At least for male patients with chronic heart failure, LOY ≥17% appears to be an independent risk factor for increased mortality, and its co‐occurrence with CHIP may partly confound the prognostic significance of DNMT3A/TET2 CHIP‐driver mutations. Here, TET2 is linked to congestive heart failure.